Search clinical trials for: SHR-1314

Total 2161 results

Shandong Cancer Hospital and Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC

Non-Small-Cell Lung Cancer

China
Northwell Health
Cohen Children's Medical Center

Available

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

Neuroblastoma | Pheochromocytoma

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Healthy

Netherlands
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma

Advanced Melanoma

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

Extranodal NK/T-cell Lymphoma, Nasal Type

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Moderate to Severe Atopic Dermatitis
Guangdong Hengrui Pharmaceutical Co., Ltd

Enrolling by invitation

Safety and Tolerance of Increased Doses of SHR-2106 Injection in Healthy Subjects

Kidney Transplantation

China
Fudan University

Unknown

A Multi-cohort Phase II Study of HER2-positive and Triple-negative Breast Cancer Brain Metastases.

Breast Cancer
HK inno.N Corporation

Unknown

Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJ-15314 Phosphate in Healthy Male Subjects

Healthy

Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer

Breast Cancer

China
Fudan University

Recruiting

A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

Advanced Salivary Gland Carcinoma

China
Harbin Medical University

Not yet recruiting

A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.

Extensive-stage Small-cell Lung Cancer
Cellectar Biosciences, Inc.

Completed

Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Jiangsu HengRui Medicine Co., Ltd.

Enrolling by invitation

The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.

Small-cell Lung Cancer

China
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

HER2-positive Breast Cancer

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Study of SHR-1501 Alone or in Combination With BCG in Subjects With NMIBC

High-risk NMIBC

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate SHR-1210 in Subjects With Advanced HCC

Hepatocellular Carcinoma Non-Resectable

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

Hodgkin Lymphoma, Adult

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Carcinoma, Bronchogenic | Lung Disease | Respiratory Tract Disease | Respiratory Tract Neoplasms Nec | Neoplasm, Bronchial

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1701 in Patients With Recurrent/Metastatic Scchn

Squamous Cell Carcinoma of Head and Neck

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Relapsed or Advanced Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects

Advanced Solid Tumors

China
Zai Lab (Shanghai) Co., Ltd.
Zai Lab (US) LLC

Recruiting

An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer

SCLC

United States, China
DualityBio Inc.

Recruiting

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumor

United States, China
Yale University

Withdrawn

A Clinical Trial Evaluating the Safety and Clinical Activity of Radioiodide (131I-) as a Novel Targeted Therapy for Metastatic Breast Cancer That Overexpresses Functional Na/I Symporter

Breast Cancer

United States
Boehringer Ingelheim

Terminated

Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
TransMolecular

Unknown

A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma

Astrocytoma | Glioblastoma Multiforme | Malignant Glioma | GBM | Oligodendroglioma

United States
Euclises Pharmaceuticals, Inc.

Recruiting

ECP-1014 Treatment for Patients With Solid Tumor Cancers

Solid Tumor

China
The First Affiliated Hospital of Xiamen University

Not yet recruiting

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric/Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Centre Jean Perrin

Recruiting

Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012 (MELRIV-1)

Melanoma

France
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Nasopharyngeal Carcinoma

China
Hangzhou Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer

Esophageal Neoplasms | Esophageal Diseases | Esophageal Squamous Cell Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

Advanced Esophageal Squamous Cell Cancer

China
ABM Therapeutics Shanghai Company Limited

Recruiting

A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors

Primary Malignant Brain Tumor

China
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Available

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

Central Nervous System/Leptomeningeal Neoplasms

United States
Cellectar Biosciences, Inc.

Active, not recruiting

Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma (CLOVER-2)

Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | Pediatric Brain Tumor | DIPG | Pediatric Solid Tumor | Pediatric Lymphoma

United States, Australia, Canada
Hebei Medical University Fourth Hospital

Not yet recruiting

Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

Breast Cancer
Shanghai Chest Hospital

Not yet recruiting

A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. (CAMFA-L)

NSCLC

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

Breast Cancer | Solid Tumor | Gastrointestinal Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Ovarian Cancer

China
RenJi Hospital

Recruiting

Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma (RJBLC-NEBC001)

Bladder Cancer | Neuroendocrine Carcinoma of the Bladder

China
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

Kidney Cancer

United States
Genzyme, a Sanofi Company

Completed

Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration

Thyroid Neoplasms
Radboud University Medical Center

Unknown

Does Radioiodine Treatment Prevent Atrial Fibrillation and Bone Loss in Endogenous Subclinical Hyperthyroidism?

Hyperthyroidism

Netherlands
The Fourth Affiliated Hospital of Zhejiang University...

Recruiting

Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

Colorectal Cancer Metastatic

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer

HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)

Recruiting

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

High-Grade Glioma

United States, Canada
Fudan University
Shanghai Shen Kang Hospital Development Center

Recruiting

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Urinary Bladder Neoplasms | Immunotherapy

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer

Esophageal Cancer

China

3

Subscribe